The findings of various studies indicate that NLRP3 inhibitors, such as OLT1177® can decrease NLRP3 activity, reduce the release of proinflammatory IL-1β, and alleviate pathophysiological features in mouse models of allergic asthma (7). The gene discussed is IL1B; the disease is allergic asthma.